View clinical trials related to Depressive Disorder, Major.Filter by:
The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 [HDRS17], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 [HAM-D6]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale [RRS], Sleep and Worry visual analogue scale [VAS], quantitative electro-encephalography [qEEG], heart rate variability [HRV] and others).
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
The primary purpose of this study is to investigate neural mechanisms and predictors of treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major Depressive Disorder.
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) in treatment-resistant depression (TRD). However, the results of placebo-controlled trials have been mixed. Here the investigators will explore whether active DBS in habeluna for TRD will result in better symptom improvement than sham DBS. This study will also use structural and functional MRI to identify the brain network changes between pre-operative, post operative active DBS and shame DBS.
Lithium is highly effective in the treatment of bipolar disorder. This study aims to investigate, for the first time, the impact of lithium monotherapy on the structural and functional connectivity of the brain using MRI imaging.
This trial attempts to evaluate the treatment efficacy of Simplified Cognitive Behavioral Therapy (SCBT) and its safety among schizophrenia patients. Half of participants will be randomized to accept SCBT.
Objectives: The effect of acupuncture as treatment for chronic pain and depression comorbidity is questionable because only a limited number of controlled clinical trials with sound methodologies have been conducted. The investigators will perform a well-designed crossover study including assessments of scales and blood sample analysis to investigate the efficacy of acupuncture as treatment for comorbidity of chronic pain and major depression disorder (MDD) and figure out the indicative biomarkers to predict or assess the comorbidity. Methods: Patients with a recent major depression and chronic pain were randomized to receive acupuncture for depression group or acupuncture for chronic pain. They will receive 2~3 sessions per week over 6 consecutive weeks. Then patients accept another 6weeks sessions after two-week washout. During washout period, original western treatment will be maintained and acupuncture will be interrupted. The primary outcome measure was change in 21-item Hamilton Depression Rating Scale (HAMD), pain with Brief Pain Inventory- Long form (BPI). Secondary outcome measures included changes in Beck Depression Inventory-II (BDI-II), Neurotoxicity Rating Scale (NTRS), WHO Quality of Life (WHOQoL), Clinical Global Impression (CGI), biomarkers such as neurotransmitter, kinase, protein, cytokine, DNA, mRNA related to comorbidity of chronic pain and major depression.